Mercy Technologies

Mercy BioAnalytics is a biotechnology company focused on the early detection of cancer through its proprietary Mercy Halo liquid biopsy platform. The technology analyzes extracellular vesicles (EVs), which are abundant in the blood and carry cancer-specific signatures, to identify disease at its earliest, most treatable stages. By detecting the colocalization of multiple biomarkers on individual EVs, the platform achieves high sensitivity and specificity compared to traditional liquid biopsy methods. The company's initial clinical focus is on developing screening tests for ovarian and lung cancers, addressing significant unmet needs in oncology diagnostics. Headquartered in Natick, Massachusetts, Mercy BioAnalytics is backed by prominent life science investors and aims to transform cancer care through accessible, high-performance blood tests.